AQST - Aquestive Therapeutics Inc Stock Price, Fair Value and News

3.51USD+0.23 (+7.01%)Delayed

Market Summary

USD3.51+0.23

Delayed

7.01%

AQST Stock Price

View Fullscreen

AQST RSI Chart

AQST Valuation

Market Cap

257.3M

Price/Earnings (Trailing)

-32.69

Price/Sales (Trailing)

4.92

EV/EBITDA

4.6K

Price/Free Cashflow

-34.89

AQST Price/Sales (Trailing)

AQST Profitability

EBT Margin

-14.59%

Return on Equity

7.39%

Return on Assets

-13.71%

Free Cashflow Yield

-2.87%

AQST Fundamentals

AQST Revenue

Revenue (TTM)

52.3M

Rev. Growth (Yr)

7.81%

Rev. Growth (Qtr)

-11.43%

AQST Earnings

Earnings (TTM)

-7.9M

Earnings Growth (Yr)

34.33%

Earnings Growth (Qtr)

-298.57%

Breaking Down AQST Revenue

Last 7 days

-13.8%

Last 30 days

-19.9%

Last 90 days

33.5%

Trailing 12 Months

79.1%

How does AQST drawdown profile look like?

AQST Financial Health

Current Ratio

2.24

Debt/Equity

-0.26

Debt/Cashflow

-0.23

AQST Investor Care

Shares Dilution (1Y)

31.20%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	49.9M	49.9M	51.4M	52.3M
2022	52.0M	49.9M	48.1M	47.7M
2021	48.2M	41.9M	46.9M	50.8M
2020	48.7M	59.3M	55.1M	45.8M
2019	56.7M	53.9M	53.0M	52.6M
2018	73.9M	76.7M	62.8M	67.4M
2017	0	0	0	66.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aquestive Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	schobel alexander mark	sold	-300,000	6.00	-50,000	chief innovation/tech officer
Mar 10, 2024	jung cassie	sold (taxes)	-5,524	4.88	-1,132	svp, operations
Mar 10, 2024	wargacki stephen	sold (taxes)	-8,232	4.88	-1,687	svp, research & development
Mar 09, 2024	barber daniel	sold (taxes)	-185,137	4.88	-37,938	president and ceo
Mar 09, 2024	wargacki stephen	sold (taxes)	-54,992	4.88	-11,269	svp, research & development
Mar 09, 2024	boyd peter e.	sold (taxes)	-40,845	4.88	-8,370	see remark
Mar 09, 2024	braender lori j	sold (taxes)	-51,386	4.88	-10,530	svp, general counsel
Mar 09, 2024	jung cassie	sold (taxes)	-40,504	4.88	-8,300	svp, operations
Mar 09, 2024	schobel alexander mark	sold (taxes)	-28,767	4.88	-5,895	chief innovation/tech officer
Mar 09, 2024	toth a ernest jr	sold (taxes)	-57,120	4.88	-11,705	svp, chief financial officer

Which funds bought or sold AQST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Financial Advocates Investment Management	unchanged	-	44,800	85,200	-%
May 01, 2024	Janney Montgomery Scott LLC	new	-	1,456,000	1,456,000	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	unchanged	-	2.00	4.00	-%
May 01, 2024	CREATIVE FINANCIAL DESIGNS INC /ADV	new	-	2,982	2,982	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-30,003	-	-%
Apr 22, 2024	PFG Investments, LLC	new	-	204,480	204,480	0.01%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	new	-	70,290	70,290	-%
Apr 19, 2024	TRUST POINT INC.	added	37.09	38,374	58,665	-%
Apr 18, 2024	Dixon Mitchell Investment Counsel Inc.	new	-	17,040	17,040	-%

Are Funds Buying or Selling AQST?

Are funds buying AQST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AQST

No. of Funds

Unveiling Aquestive Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	venrock healthcare capital partners iii, l.p.	6.5%	5,555,555	SC 13G
Feb 14, 2024	armistice capital, llc	5.88%	3,924,000	SC 13G
Feb 11, 2022	bratton douglas k	8.6%	3,468,747	SC 13G/A
Feb 16, 2021	perceptive advisors llc	4.1%	1,385,720	SC 13G/A
Feb 09, 2021	bratton douglas k	12.0%	13	SC 13G/A
Dec 01, 2020	madryn asset management, lp	4.2%	1,530,717	SC 13G/A
Feb 14, 2020	perceptive advisors llc	7.0%	2,250,000	SC 13G/A
Feb 12, 2020	bratton douglas k	16.1%	13	SC 13G/A
Sep 09, 2019	madryn asset management, lp	5.5%	1,428,572	SC 13G

Recent SEC filings of Aquestive Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	8-K	Current Report
Apr 26, 2024	3	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 24, 2024	424B2	Prospectus Filed
Apr 24, 2024	424B2	Prospectus Filed
Apr 23, 2024	EFFECT	EFFECT
Apr 22, 2024	8-K	Current Report
Apr 03, 2024	S-3	S-3

Peers (Alternatives to Aquestive Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	359.2B	85.6B	-3.24%	-7.94%	9.34	4.19	5.68%	202.39%
MRK	323.0B	61.4B	-1.84%	8.64%	140.05	5.26	6.11%	-82.30%
AMGN	166.9B	29.5B	13.40%	34.20%	44.36	5.65	12.76%	-52.47%
PFE	157.1B	46.5B	2.20%	-27.23%	-113.14	3.37	42.59%	-114.62%
GILD	80.7B	27.1B	-8.62%	-17.50%	14.25	2.98	-0.60%	23.36%
TEVA	15.6B	15.8B	-0.99%	61.25%	-27.18	0.99	6.17%	76.47%
MID-CAP
PRGO	4.4B	4.7B	5.70%	-11.21%	-349.99	0.95	4.58%	90.97%
ALKS	4.1B	1.7B	-8.55%	-16.13%	9.38	2.36	54.01%	364.56%
BHC	2.9B	9.0B	-22.11%	32.77%	-6.3	0.32	10.01%	-27.45%
AMPH	2.0B	644.4M	1.22%	16.11%	14.84	3.17	29.14%	50.51%
SMALL-CAP
TLRY	1.6B	743.2M	-26.67%	-17.06%	-4.6	2.18	24.65%	80.36%
TXMD	22.0M	1.3M	-14.35%	-52.84%	-2.14	16.92	-98.14%	-109.18%
ACRX	17.1M	-	-	62.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	35.71%	-93.63%	-0.17	0.13	80.00%	43.08%
ACOR	1.1M	117.6M	-94.70%	-92.62%	0	0.01	-0.79%	-283.60%

Aquestive Therapeutics Inc News

Latest updates

Aquestive Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-11.4%	11,516,500	13,002,000	13,241,000	14,513,000	10,682,000	11,463,000	13,265,000	12,270,000	11,078,000	13,287,000	15,345,000	11,122,000	7,149,000	8,260,000	21,675,000	8,765,000	16,419,000	12,418,000	11,129,000	12,643,000	16,824,000
Costs and Expenses	11.3%	17,117,000	15,379,000	17,450,000	15,739,000	21,395,000	20,316,000	26,027,000	22,008,000	-	21,255,000	21,862,000	19,647,000	22,795,000	22,041,000	21,280,000	22,626,000	26,323,000	23,420,000	29,817,000	25,717,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	16,373,000	-	-	22,626,000	26,323,000	23,420,000	29,817,000	25,717,000	29,173,000
S&GA Expenses	29.3%	9,550,000	7,385,000	7,360,000	7,455,000	11,812,000	12,459,000	15,587,000	13,021,000	14,981,000	12,129,000	13,134,000	13,231,000	15,582,000	11,803,000	13,894,000	14,613,000	16,474,000	13,714,000	16,246,000	17,908,000	18,698,000
R&D Expenses	-9.6%	2,888,000	3,196,000	3,473,000	3,547,000	4,278,000	3,232,000	5,198,000	4,773,000	4,400,000	4,726,000	4,262,000	3,659,000	4,425,000	7,260,000	3,847,000	4,354,000	3,057,000	5,063,000	8,151,000	4,303,000	5,683,000
EBITDA Margin	101.1%	0.00	-0.10	-0.29	-0.50	-0.95	-1.28	-1.25	-1.10	-1.13	-1.01	-1.19	-0.82	-	-	-	-	-	-	-	-	-
Interest Expenses	81.0%	2,273,000	1,256,000	1,373,000	1,435,000	1,650,000	1,649,000	1,635,000	1,618,000	1,744,000	2,787,000	2,757,000	2,761,000	2,768,000	2,778,000	2,747,000	2,771,000	2,803,000	2,652,000	1,937,000	1,926,000	1,913,000
Income Taxes	172.1%	101,000	-140,000	284,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-268.3%	-8,010,000	-2,175,000	-5,508,000	8,068,000	-12,352,000	-12,536,000	-16,302,000	-13,220,000	-28,945,000	-14,555,000	-12,367,000	-14,672,000	-20,368,000	-16,551,000	-2,334,000	-16,530,000	-12,636,000	-18,412,000	-20,472,000	-14,726,000	-13,944,000
EBT Margin	37.3%	-0.15	-0.23	-0.45	-0.66	-1.14	-1.48	-1.46	-1.33	-1.39	-1.32	-1.53	-1.12	-	-	-	-	-	-	-	-	-
Net Income	-298.6%	-8,111,000	-2,035,000	-5,792,000	8,068,000	-12,352,000	-12,536,000	-16,302,000	-13,220,000	-28,945,000	-14,555,000	-12,367,000	-14,672,000	-20,368,000	-16,551,000	-2,334,000	-16,530,000	-12,636,000	-18,412,000	-20,472,000	-14,726,000	-13,944,000
Net Income Margin	36.1%	-0.15	-0.24	-0.45	-0.66	-1.14	-1.48	-1.46	-1.33	-1.39	-1.32	-1.53	-1.12	-	-	-	-	-	-	-	-	-
Free Cashflow	-98.5%	-4,958,000	-2,498,000	-8,733,000	8,814,000	8,420,000	2,592,000	-7,239,000	-14,586,000	-8,594,000	-9,148,000	-1,950,000	-14,200,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.4%	57.00	59.00	57.00	61.00	57.00	52.00	56.00	57.00	62.00	65.00	67.00	62.00	63.00	50.00	64.00	64.00	78.00	49.00	50.00	68.00	87.00
Current Assets	-3.5%	41.00	42.00	40.00	44.00	40.00	38.00	44.00	43.00	47.00	50.00	51.00	44.00	45.00	32.00	44.00	51.00	68.00	38.00	39.00	56.00	74.00
Cash Equivalents	-4.2%	24.00	25.00	22.00	27.00	27.00	19.00	18.00	15.00	28.00	31.00	34.00	27.00	32.00	17.00	25.00	36.00	49.00	21.00	22.00	40.00	61.00
Inventory	-4.4%	7.00	7.00	6.00	7.00	6.00	7.00	5.00	5.00	4.00	3.00	3.00	3.00	2.00	3.00	3.00	3.00	3.00	4.00	5.00	5.00	5.00
Net PPE	-8.2%	4.00	5.00	5.00	4.00	4.00	4.00	5.00	4.00	5.00	5.00	6.00	6.00	7.00	8.00	8.00	9.00	10.00	10.00	11.00	12.00	12.00
Liabilities	0.9%	164	162	164	171	176	160	153	150	144	126	121	114	111	87.00	85.00	85.00	85.00	83.00	75.00	74.00	77.00
Current Liabilities	-23.9%	18.00	24.00	39.00	40.00	40.00	37.00	30.00	24.00	22.00	25.00	23.00	20.00	21.00	18.00	15.00	15.00	19.00	20.00	25.00	30.00	33.00
Long Term Debt	-	28.00	-	-	-	33.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-106	-	-	-	-118	-	-	-	-82.13	-	-	-	-	-	-	-	-	-	-	-	10.00
Retained Earnings	-2.6%	-319	-310	-308	-303	-311	-298	-286	-270	-256	-227	-213	-200	-186	-165	-149	-147	-130	-117	-99.43	-78.95	-61.38
Additional Paid-In Capital	2.2%	213	208	202	194	193	191	190	177	175	167	159	149	138	129	128	126	124	83.00	75.00	73.00	71.00
Shares Outstanding	2.7%	69.00	67.00	62.00	56.00	55.00	53.00	45.00	41.00	41.00	39.00	36.00	36.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	83.00	-	-	-	28.00	-	-	-	111	-	-	-	102	-	-	-	101	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-110.6%	-4,942	-2,347	-7,907	8,816	8,416	2,809	-6,562	-14,482	-8,061	-9,065	-1,756	-14,097	-13,512	-8,313	-9,997	-13,637	-10,575	-14,789	-17,166	-17,680	-2,812
Share Based Compensation	21.4%	940	774	631	344	714	535	2,219	913	1,691	1,900	1,721	1,507	1,529	1,427	1,765	1,860	1,872	1,869	1,810	1,520	1,399
Cashflow From Investing	89.4%	-16.00	-151	-826	-2.00	-26.00	-1,717	-677	-104	-533	-83.00	-194	-103	-236	-38.00	-112	-131	-86.00	-91.00	-110	-376	-490
Cashflow From Financing	-21.4%	3,913	4,979	4,287	-9,205	234	-138	10,198	1,298	5,454	6,078	8,686	9,891	28,491	-7.00	10.00	-37.00	39,073	13,629	-493	-2,609	-81.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AQST Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 50,583	$ 47,680
Costs and expenses:
Manufacture and supply	20,831	19,386
Research and development	13,104	17,481
Selling, general and administrative	31,750	52,879
Total costs and expenses	65,685	89,746
Loss from operations	(15,102)	(42,066)
Other income (expenses):
Interest expense	(6,337)	(6,552)
Interest expense related to royalty obligations, net	(905)	0
Interest expense related to the sale of future revenue	(220)	(5,891)
Interest income and other income, net	16,321	99
Loss on the extinguishment of debt	(1,382)	0
Net loss before income taxes	(7,625)	(54,410)
Income taxes	(245)	0
Net loss	(7,870)	(54,410)
Comprehensive loss	$ (7,870)	$ (54,410)
Net loss per share – basic and diluted
Basic (in dollars per share)	$ (0.13)	$ (1.12)
Diluted (in dollars per share)	$ (0.13)	$ (1.12)
Weighted-average number of common shares outstanding - basic and diluted
Basic (in shares)	61,255,864	48,734,377
Diluted (in shares)	61,255,864	48,734,377

AQST Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,872	$ 27,273
Trade and other receivables, net	8,471	4,704
Inventories, net	6,769	5,780
Prepaid expenses and other current assets	1,854	2,131
Total current assets	40,966	39,888
Property and equipment, net	4,179	4,085
Right-of-use assets, net	5,557	5,211
Intangible assets, net	1,278	1,435
Other non-current assets	5,438	6,451
Total assets	57,418	57,070
Current liabilities:
Accounts payable	8,926	9,946
Accrued expenses	6,497	7,967
Lease liabilities, current	390	255
Deferred revenue	1,551	1,513
Liability related to the sale of future revenue, current	922	1,147
Notes payable, current	22	18,700
Total current liabilities	18,308	39,528
Notes payable, net	27,508	33,448
Royalty obligations, net	14,761	0
Liability related to the sale of future revenue, net	63,568	64,112
Lease liabilities	5,399	5,085
Deferred revenue, net of current portion	32,345	31,417
Other non-current liabilities	2,016	2,034
Total liabilities	163,905	175,624
Contingencies (Note 22)
Stockholders’ deficit:
Common stock, 0.001 par value. Authorized 250,000,000 shares; 68,533,085 and 54,827,734 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	69	55
Additional paid-in capital	212,521	192,598
Accumulated deficit	(319,077)	(311,207)
Total stockholders’ deficit	(106,487)	(118,554)
Total liabilities and stockholders’ deficit	$ 57,418	$ 57,070

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

CEO	Mr. Daniel Barber
WEBSITE	aquestive.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	130

Aquestive Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aquestive Therapeutics Inc? What does AQST stand for in stocks?

AQST is the stock ticker symbol of Aquestive Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aquestive Therapeutics Inc (AQST)?

As of Fri May 03 2024, market cap of Aquestive Therapeutics Inc is 257.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AQST stock?

You can check AQST's fair value in chart for subscribers.

What is the fair value of AQST stock?

You can check AQST's fair value in chart for subscribers. The fair value of Aquestive Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aquestive Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AQST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aquestive Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AQST is over valued or under valued. Whether Aquestive Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aquestive Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AQST.

What is Aquestive Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, AQST's PE ratio (Price to Earnings) is -32.69 and Price to Sales (PS) ratio is 4.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AQST PE ratio will change depending on the future growth rate expectations of investors.